{"entity":{"id":"nct04060394","kind":"trial","name":"Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC","aka":[],"tldr":"A phase 1/2 trial of Afuresertib and Lapiteronel run by Laekna Limited, completed.","summary":"Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC is a phase 1/2 interventional study registered as NCT04060394 by Laekna Limited, with 49 participants enrolled, started 2019-09-13, primary completion reached 2023-12-27. Conditions recorded: Metastatic Castration-resistant Prostate Cancer. Interventions recorded: Phase I and Phase II: LAE001/prednisone + afuresertib.","status":"completed","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT04060394","url":"https://clinicaltrials.gov/study/NCT04060394"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["afuresertib","lapiteronel"],"companies":["laekna-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04060394","phase":"1/2","setting":"A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment","sponsor":"Laekna Limited","enrolled":49,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04060394/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"drug":[{"id":"afuresertib","kind":"drug","name":"Afuresertib","route":"/drugs/afuresertib/"},{"id":"lapiteronel","kind":"drug","name":"Lapiteronel","route":"/drugs/lapiteronel/"}],"company":[{"id":"laekna-therapeutics","kind":"company","name":"Laekna Therapeutics","route":"/companies/laekna-therapeutics/"}]}}